A recent expose examined the practice of surgeons double-booking surgery–and why it is wrong. Medscape
Uncategorized
Second Sight Reports Third Quarter 2015 Financial Results
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today report…
Uncategorized
VIDEO: Cataract surgeons need to evaluate MIGS devices
NEW YORK — With up to 20% to 25% of patients having either ocular hypertension or glaucoma, it is important for cataract surgeons to evaluate new glaucoma procedures, according to a speaker here.“What used to be a disease we needed to manage for about 15 years is now a disease we need to manage for about 40 years, and because of that, we really want to take advantage of each of the steps that we have been taking for glaucoma patients,” Savak “Sev” Teymoorian, MD, MBA, said at OSN New York 2015.
Uncategorized
Allergan, Pfizer confirm discussions over potential merger
Allergan today announced that it has been approached by Pfizer and is in preliminary discussions regarding a potential business combination transaction, according to a press release.“No agreement has been reached and there can be no certainty that these discussions will lead to a transaction, or as to the terms on which a transaction, if any, might be agreed,” Allergan stated in the release.
Controversies in Femtosecond Laser-Assisted Cataract Surgery
Femtosecond laser-assisted cataract surgery is becoming more widely available, but its role is still controversial. Where does this technology fit in to resident surgical training? International Ophthalmology Clinics
Uncategorized
Ophthotech completes patient recruitment in phase 3 trial of Fovista in combination with Lucentis
Ophthotech has completed patient recruitment in the second phase 3 trial of Fovista in combination with Lucentis for the treatment of wet age-related macular degeneration, the company announced in a press release. The two phase 3 clinical trials are investigating the superiority of Fovista (pegpleranib, Ophthotech) in combination with Lucentis (ranibizumab, Genentech) over Lucentis monotherapy. Data from the two clinical trials will be analyzed together “to optimize pooled analysis of certain relevant endpoints in accordance with the statistical analysis plan,” the release said.